The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...
They also found that targeting a pathway, called CXCR4, that is turned on in these cells can inhibit granulomas from forming. These findings suggest that clinicians may be able to diagnose ...
Hosted on MSN3mon
Q&A: Improving liver cancer outcomes through enhanced immunotherapyOur previous reports have focused on the tumor microenvironment in liver cancer, including the role of CXCR4, a receptor for CXCL12, which helps weaken the immune system's ability to fight cancer ...
Exicure (XCUR) announced that the Australian Patent Office has issued Patent No. 2018388302, titled “GPCR Heteromer Inhibitors and Uses ...
Now, Bernhagen and colleagues, writing in Nature Medicine, have identified MIF as a ligand for the CXC-chemokine receptors CXCR2 and CXCR4, and suggest that targeting MIF could be used as an ...
Exicure, Inc. (Nasdaq: XCUR) today announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." This patent covers the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback